메뉴 건너뛰기
Current Oncology Reports
Volumn 6, Issue 6, 2004, Pages 421-422
Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial
Author keywords

[No Author keywords available]
Indexed keywords

ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; FLUOROURACIL; GEFITINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL;
EID: 9744257793     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0070-x     Document Type: Editorial
Times cited : (2)
References (6)
  • 1
    • 2442696436 scopus 로고    scopus 로고
    • Prognostic importance of comorbidity in a hospital-based cancer registry
    • Piccirillo JF, Tierney RM, Costas I, et al.: Prognostic importance of comorbidity in a hospital-based cancer registry JAMA 2004, 291:2441-2447.
    • (2004) JAMA , vol.291 , pp. 2441-2447
    • Piccirillo, J.F.1    Tierney, R.M.2    Costas, I.3
  • 2
    • 2942739224 scopus 로고    scopus 로고
    • Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: Pooled analysis from three multicenter, randomized, controlled trials using individual patient data
    • Chau I, Norman AR, Cunningham D, et al.: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 2004, 22:2395-2403.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 2395-2403
    • Chau, I.1    Norman, A.R.2    Cunningham, D.3
  • 3
    • 2942744745 scopus 로고    scopus 로고
    • High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial
    • Zabder AF, Kroger N, Schmoor C, et al.: High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004, 22:2273-2283.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 2273-2283
    • Zabder, A.F.1    Kroger, N.2    Schmoor, C.3
  • 4
    • 2942655407 scopus 로고    scopus 로고
    • Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342
    • Winer EP, Berry DA, Woolf S, et al.: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol 2004, 22:2061-2068.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 2061-2068
    • Winer, E.P.1    Berry, D.A.2    Woolf, S.3
  • 5
    • 3042698692 scopus 로고    scopus 로고
    • Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group Chemotherapy trials
    • Durie BGM, Jacobson J, Barlogie B, et al.: Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group Chemotherapy trials. J Clin Oncol 2004, 22:1857-1863.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 1857-1863
    • Durie, B.G.M.1    Jacobson, J.2    Barlogie, B.3
  • 6
    • 3042741125 scopus 로고    scopus 로고
    • Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?
    • Shanafelt TD, Loprinzi C, Marks R, et al.: Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004, 22:1966-1974.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 1966-1974
    • Shanafelt, T.D.1    Loprinzi, C.2    Marks, R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.